American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings

Endocrine Practice, Journal Year: 2022, Volume and Issue: 28(5), P. 528 - 562

Published: May 1, 2022

Language: Английский

---

A global view of the interplay between non-alcoholic fatty liver disease and diabetes

The Lancet Diabetes & Endocrinology, Journal Year: 2022, Volume and Issue: 10(4), P. 284 - 296

Published: Feb. 17, 2022

Language: Английский

---

Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis

˜The œLancet. Gastroenterology & hepatology, Journal Year: 2021, Volume and Issue: 6(11), P. 903 - 913

Published: Sept. 21, 2021

Language: Английский

---

MASLD: a systemic metabolic disorder with cardiovascular and malignant complications

Gut, Journal Year: 2024, Volume and Issue: unknown, P. gutjnl - 330595

Published: Jan. 16, 2024

Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common chronic globally and is currently estimated to affect up 38% of global adult population. NAFLD a multisystem where systemic insulin resistance related metabolic dysfunction play pathogenic role in development its relevant liver-related morbidities (cirrhosis, failure hepatocellular carcinoma) extrahepatic complications, such as cardiovascular (CVD), type 2 diabetes mellitus, kidney disease, certain types cancers. In 2023, three large multinational associations proposed that dysfunction-associated steatotic (MASLD) should replace term NAFLD; name chosen non-alcoholic steatohepatitis was (MASH). Emerging epidemiological evidence suggests an excellent concordance rate between MASLD definitions—that is, ~99% individuals with meet criteria. this narrative review, we provide overview literature on (a) recent data risk developing CVD malignant (b) underlying mechanisms by which (and factors strongly linked MASLD) may increase these complications (c) diagnosis assessment potential treatments reduce people or MASH.

Language: Английский

---

Mitochondrial alterations in fatty liver diseases

Journal of Hepatology, Journal Year: 2022, Volume and Issue: 78(2), P. 415 - 429

Published: Oct. 7, 2022

Fatty liver diseases can result from common metabolic diseases, as well xenobiotic exposure and excessive alcohol use, all of which have been shown to exert toxic effects on hepatic mitochondrial functionality dynamics. Invasive or complex methodology limits large-scale investigations mitochondria in human livers. Nevertheless, abnormal function, such impaired fatty acid oxidation oxidative phosphorylation, drives stress has identified an important feature steatohepatitis. On the other hand, be flexible adapt ambient condition prevent triglyceride lipotoxin accumulation obesity. Experience studies xenobiotics provided insights into regulation mitochondria. Increasing awareness joint presence disease-related (lipotoxic) alcohol-related further highlights need better understand their mutual interaction potentiation disease progression. Recent clinical assessed diets bariatric surgery mitochondria, are also evolving interesting therapeutic target non-alcoholic disease. This review summarises current knowledge with a focus linked obesity, type 2 diabetes xenobiotics.

Language: Английский

---

Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review

˜The œLancet. Gastroenterology & hepatology, Journal Year: 2022, Volume and Issue: 7(4), P. 367 - 378

Published: Jan. 12, 2022

Language: Английский

---

The associations between modifiable risk factors and nonalcoholic fatty liver disease: A comprehensive Mendelian randomization study

Hepatology, Journal Year: 2022, Volume and Issue: 77(3), P. 949 - 964

Published: Aug. 16, 2022

Background and Aims: Early identification of modifiable risk factors is essential for the prevention nonalcoholic fatty liver disease (NAFLD). We aimed to systematically explore relationships between genetically predicted NAFLD. Approach Results: applied univariable multivariable Mendelian randomization analyses 35 also evaluated combined results in three independent large genome‐wide association studies. Genetically alcohol frequency, elevated serum levels enzymes, triglycerides, C‐reactive protein, obesity traits, including body mass index, waist circumference, fat mass, were associated with increased risks NAFLD (all p < 0.05). Poor physical condition had a suggestive (odds ratio [OR] = 2.63, 0.042). instrumented type 2 diabetes (T2DM), hypothyroidism, hypertension all NAFLD, ORs (95% confidence interval) 1.508 (1.20–1.90), 13.08 (1.53–111.65), 3.11 (1.33–7.31) 1‐U increase log‐transformed odds, respectively. The positive associations T2DM remained significant analyses. from discovery two replication datasets further confirmed that poor condition, T2DM, significantly whereas higher education high‐density lipoprotein cholesterol (HDL‐cholesterol) could lower risk. Conclusions: an HDL‐cholesterol decreased

Language: Английский

---

The role of hepatokines in NAFLD

Cell Metabolism, Journal Year: 2023, Volume and Issue: 35(2), P. 236 - 252

Published: Feb. 1, 2023

Language: Английский

---

Metabolic syndrome – a new definition and management guidelines A joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, “Club 30” Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons

Archives of Medical Science, Journal Year: 2022, Volume and Issue: 18(5), P. 1133 - 1156

Published: Aug. 30, 2022

1. Visseren FLJ, Mach F, Smulders YM, . ESC National Cardiac Societies, Scientific Document Group. 2021 Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42: 3227-37. Google Scholar

Language: Английский

---

Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis

Gut, Journal Year: 2023, Volume and Issue: 72(11), P. 2138 - 2148

Published: July 25, 2023

Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic disease, with type 2 diabetes mellitus (T2DM) as a major predictor. Insulin resistance and inflammation are key pathways in pathogenesis T2DM to NAFLD vice versa, synergistic effect increasing morbidity mortality risks. This meta-analysis aims quantify prevalence clinically significant advanced fibrosis people T2DM.MEDLINE Embase databases were searched from inception until 13 February 2023. The primary outcomes NAFLD, non-alcoholic steatohepatitis (NASH) T2DM. A generalised linear mixed model Clopper-Pearson intervals was used for analysis proportions sensitivity conducted explore heterogeneity between studies.156 studies met inclusion criteria, pooled 1 832 125 patients determined that rates NASH 65.04% (95% CI 61.79% 68.15%, I2=99.90%) 31.55% 17.12% 50.70%, I2=97.70%), respectively. 35.54% 19.56% 55.56%, I2=100.00%) individuals had (F2-F4), while 14.95% 11.03% 19.95%, I2=99.00%) (F3-F4).This study high Increased efforts required prevent combat rising burden NAFLD.CRD42022360251.

Language: Английский

---